Adage Capital Partners Gp, L.L.C. Dyne Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

$51 Billion
Q1 2024

A detailed history of Adage Capital Partners Gp, L.L.C. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Adage Capital Partners Gp, L.L.C. holds 2,325,000 shares of DYN stock, worth $74.1 Million. This represents 0.13% of its overall portfolio holdings.

Number of Shares

2,325,000

Holding current value

$74.1 Million

% of portfolio

0.13%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$13.06 - $29.18 $30.4 Million - $67.8 Million	2,325,000 New	2,325,000 $66 Million
Q2 2023 Aug 14, 2023	SELL	$8.53 - $14.28 $4.27 Million - $7.14 Million	-500,000 Reduced 83.33%	100,000 $1.13 Million
Q1 2023 May 15, 2023	BUY	$10.88 - $15.0 $2.18 Million - $3 Million	200,000 Added 50.0%	600,000 $6.91 Million
Q4 2022 Feb 14, 2023	SELL	$9.37 - $13.8 $468,499 - $690,000	-50,000 Reduced 11.11%	400,000 $4.64 Million
Q3 2022 Nov 14, 2022	SELL	$7.2 - $15.17 $864,000 - $1.82 Million	-120,000 Reduced 21.05%	450,000 $5.72 Million

Q2 2022 Aug 15, 2022	SELL	$4.36 - $10.5 $784,800 - $1.89 Million	-180,000 Reduced 24.0%	570,000 $3.92 Million
Q1 2022 May 16, 2022	BUY	$6.52 - $12.27 $4.24 Million - $7.98 Million	650,000 Added 650.0%	750,000 $7.23 Million
Q4 2021 Feb 14, 2022	BUY	$11.89 - $16.07 $594,500 - $803,500	50,000 Added 100.0%	100,000 $1.19 Million
Q3 2021 Nov 15, 2021	SELL	$15.6 - $21.46 $780,000 - $1.07 Million	-50,000 Reduced 50.0%	50,000 $812,000
Q2 2021 Aug 16, 2021	BUY	$15.94 - $22.33 $1.59 Million - $2.23 Million	100,000 New	100,000 $2.1 Million

Others Institutions Holding DYN

# of Institutions

176

Shares Held

87.1M

Call Options Held

130K

Put Options Held

209K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $1.65B
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

News

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.

Account

Adage Capital Partners Gp, L.L.C. Dyne Therapeutics, Inc. Transaction History